<?xml version="1.0" encoding="UTF-8"?>
<ref id="B7">
 <label>7</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Seymour</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Bogaerts</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Perrone</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Ford</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Schwartz</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Mandrekar</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Irecist: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics</article-title>. 
  <source>Lancet Oncol</source> (
  <year>2017</year>) 
  <volume>18</volume>(
  <issue>3</issue>):
  <page-range>e143â€“e52</page-range>. 
  <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30074-8</pub-id>
 </mixed-citation>
</ref>
